cis-2-Methyl-decahydro-isochinolin | 1719-46-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: cis-2-Methyl-decahydro-isochinolin
• 英文别名: cis-2-Methyl-decahydroisochinolin；(4aR,8aR)-2-methyl-3,4,4a,5,6,7,8,8a-octahydro-1H-isoquinoline
• CAS: 1719-46-6；21656-75-7；23994-18-5；87463-47-6；87463-48-7
• 化学式: C₁₀H₁₉N
• 分子量: 153.268
• InChiKey: MMCXKYPKYQMCRM-ZJUUUORDSA-N

物化性质

• 沸点：
  212 °C(Press: 765 Torr)
• 密度：
  0.91 g/cm3(Temp: 23 °C)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  cis-2-Methyl-decahydro-isochinolin 、 氯甲酸乙酯 以91%的产率得到
  参考文献：
  名称：

  BAILEY, J. M.;BOOTH, H.;AL-SHIRAYDA, H. A. R. Y., J. CHEM. SOC. PERKIN TRANS., 1984, N 3, 583-587

  摘要：

  DOI：
• 作为产物：
  描述：

  十氢异喹啉 、 甲酸 、 聚合甲醛 生成 cis-2-Methyl-decahydro-isochinolin
  参考文献：
  名称：

  BAILEY, J. M.;BOOTH, H.;AL-SHIRAYDA, H. A. R. Y., J. CHEM. SOC. PERKIN TRANS., 1984, N 3, 583-587

  摘要：

  DOI：

文献信息

• HIV REPLICATION INHIBITOR
  申请人：SHIONOGI & CO., LTD.

  公开号：US20150361093A1

  公开（公告）日：2015-12-17

  The present invention provides a novel compound having an antiviral activity, in particular, an HIV replication inhibiting activity, as well as a pharmaceutical composition, in particular, an anti-HIV agent. wherein ring A is substituted or unsubstituted carbocycle or substituted or unsubstituted heterocycle; R 1 is substituted or unsubstituted alkyl etc.; R 2 is substituted or unsubstituted alkyloxy etc.; n is 1 or 2; R 3 is substituted or unsubstituted carbocyclyl or substituted or unsubstituted heterocyclyl; R 4 is a hydrogen atom etc.; R 6 is substituted or unsubstituted alkyl etc.
• TRICYCLIC HETEROCYCLE DERIVATIVES HAVING HIV REPLICATION INHIBITORY EFFECT
  申请人：Shionogi & Co., Ltd.

  公开号：US20170107234A1

  公开（公告）日：2017-04-20

  The present invention provides the following compound having anti-HIV activity of formula: wherein, A 1 is C, CR 1A or N; A 2 is C, CR 2A , or N; A 3 is CR 3A , CR 3A R 3B , N, NR 3C , O, S, SO, or SO 2 ; A 4 is CR 4A , CR 4A R 4B , N, NR 4 C, O, S, SO, or SO2; A 5 is C, CR 5A , or N; T 1 ring is substituted or unsubstituted monocyclic carbocycle or substituted or unsubstituted monocyclic heterocycle; R 1 is halogen, cyano, nitro or —X 1 —R 11 ; R 2 is substituted or unsubstituted alkyl and the like; n is 1 or 2; R 3 is hydrogen, substituted or unsubstituted aromatic carbocyclyl; R 4 is hydrogen or a carboxy protecting group; the other symbols are as specified in the description.
• PHARMACEUTICAL COMPOSITION FOR INDUCING PROGRAMMED CELL DEATH IN CANCER CELLS
  申请人：KYOTO UNIVERSITY

  公开号：US20200188382A1

  公开（公告）日：2020-06-18

  A method for inducing programmed cell death in cancer cells and a pharmaceutical composition therefor are provided. Provided is a method for inducing programmed cell death in cancer cells, the method including enhancing production of nitric oxide in cancer cells. Provided is a pharmaceutical composition for inducing programmed cell death in cancer cells, the pharmaceutical composition containing, as an active component, a compound that enhances production of nitric oxide in cancer cells. Provided is use of a compound that enhances production of nitric oxide in cancer cells, in a method for preventing, improving, suppressing progression of, and/or treating cancers.
• US7157454B2
  申请人：——

  公开号：US7157454B2

  公开（公告）日：2007-01-02
• [EN] PHARMACEUTICAL COMPOSITION FOR INDUCING PROGRAMMED CELL DEATH IN CANCER CELLS<br/>[FR] COMPOSITION DE MÉDICAMENT DESTINÉE À INDUIRE DANS DES CELLULES CANCÉREUSES UNE MORT CELLULAIRE PROGRAMMÉE<br/>[JA] がん細胞にプログラム細胞死を誘導するための医薬組成物
  申请人：UNIV KYOTO

  公开号：WO2018079855A1

  公开（公告）日：2018-05-03

  がん細胞にプログラム細胞死を誘導する方法、及びそのための医薬組成物の提供。　がん細胞内において一酸化窒素の産生を亢進させることを含む、がん細胞にプログラム細胞死を誘導する方法。がん細胞内の一酸化窒素産生を亢進する化合物を有効成分として含有する、がん細胞にプログラム細胞死を誘導するための医薬組成物。がんの予防、改善、進行抑制、及び／又は、治療の方法における、がん細胞内の一酸化窒素産生を亢進する化合物の使用。